Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease

Lubor Goláň, Ozlem Goker-Alpan, Myrl Holida, Ikka Kantola, Mariusz Klopotowski, Johanna Kuusisto, Aleš Linhart, Jacek Musial, Kathleen Nicholls, Derlis Gonzalez Rodríguez, Reena Sharma, Bojan Vujkovac, Peter Chang, Anna Wijatyk
  • Drug Design Development and Therapy, July 2015, Dove Medical Press
  • DOI: 10.2147/dddt.s80928

Recommendation for initiation and cessation of enzyme replacement therapy

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

open access logoRead Publication


The following have contributed to this page: Mr Myrl D. Holida, Dr Reena Sharma, Professor JACEK MUSIAL, and Dr Bojan Vujkovac